Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance.
Adaptive immunity
Hepatitis
Immunoglobulins
Immunology
Virology
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
13 08 2019
13 08 2019
Historique:
entrez:
14
8
2019
pubmed:
14
8
2019
medline:
17
6
2020
Statut:
epublish
Résumé
A vaccine for hepatitis C virus (HCV) is urgently needed. Development of broadly-neutralizing plasma antibodies during acute infection is associated with HCV clearance, but the viral epitopes of these plasma antibodies are unknown. Identification of these epitopes could define the specificity and function of neutralizing antibodies (NAbs) that should be induced by a vaccine. Here, we present development and application of a high-throughput method that deconvolutes polyclonal anti-HCV NAbs in plasma, delineating the epitope specificities of anti-HCV NAbs in acute infection plasma of forty-four humans with subsequent clearance or persistence of HCV. Remarkably, we identified multiple broadly neutralizing antibody (bNAb) combinations that were associated with greater plasma neutralizing breadth and with HCV clearance. These studies have potential to inform new strategies for vaccine development by identifying bNAb combinations in plasma associated with natural clearance of HCV, while also providing a high-throughput assay that could identify these responses after vaccination trials.
Identifiants
pubmed: 31408439
pii: 130720
doi: 10.1172/JCI130720
pmc: PMC6819096
doi:
pii:
Substances chimiques
Broadly Neutralizing Antibodies
0
Epitopes
0
Hepatitis C Antibodies
0
Viral Hepatitis Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4786-4796Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK058404
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127469
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008752
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI088791
Pays : United States
Références
J Virol. 2016 Jan 27;90(7):3773-82
pubmed: 26819308
Sci Adv. 2019 Jan 02;5(1):eaav1882
pubmed: 30613781
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6205-10
pubmed: 22492964
AIDS. 2013 Oct 23;27(16):2551-7
pubmed: 23736152
Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):6025-30
pubmed: 17392433
J Virol. 2013 Jan;87(1):37-51
pubmed: 23097455
PLoS Pathog. 2017 Dec 18;13(12):e1006735
pubmed: 29253863
PLoS Pathog. 2019 May 17;15(5):e1007772
pubmed: 31100098
Trends Microbiol. 2018 Oct;26(10):854-864
pubmed: 29703495
Nature. 2011 Jun 08;474(7350):S2-4
pubmed: 21666731
PLoS Pathog. 2017 Feb 24;13(2):e1006235
pubmed: 28235087
Proc Natl Acad Sci U S A. 2019 May 14;116(20):10039-10047
pubmed: 31040211
Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E82-E91
pubmed: 29255018
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7271-6
pubmed: 12761383
N Engl J Med. 2013 May 16;368(20):1859-61
pubmed: 23675657
J Hepatol. 2017 Feb;66(2):267-269
pubmed: 27816493
J Virol. 2019 Jun 28;93(14):
pubmed: 31068427
Clin Infect Dis. 2005 Apr 1;40(7):951-8
pubmed: 15824985
PLoS One. 2016 Oct 24;11(10):e0165047
pubmed: 27776169
JCI Insight. 2017 May 4;2(9):null
pubmed: 28469084
Sci Transl Med. 2014 Sep 17;6(254):254ra129
pubmed: 25232181
Nat Med. 2013 Jul;19(7):869-78
pubmed: 23836237
Retrovirology. 2017 Dec 21;14(1):57
pubmed: 29268769
Nat Med. 2008 Jan;14(1):25-7
pubmed: 18064037
Vaccine. 2008 Nov 18;26(49):6189-99
pubmed: 18852005
Lancet Infect Dis. 2015 Apr;15(4):451-60
pubmed: 25703062
Hepatology. 2014 Nov;60(5):1551-62
pubmed: 25043937
J Infect. 2015 Nov;71(5):571-7
pubmed: 26212868
J Virol. 2014 Dec;88(24):14278-88
pubmed: 25275133
J Virol. 2011 Jul;85(14):7005-19
pubmed: 21543495
Front Immunol. 2018 Aug 02;9:1703
pubmed: 30116237
PLoS Pathog. 2012;8(4):e1002653
pubmed: 22511875
J Viral Hepat. 2017 May;24(5):359-370
pubmed: 28027424
Cell Host Microbe. 2018 Nov 14;24(5):717-730.e5
pubmed: 30439341
Cell Host Microbe. 2018 Nov 14;24(5):703-716.e3
pubmed: 30439340
Gastroenterology. 2019 Jan;156(2):418-430
pubmed: 30268785
J Clin Invest. 2015 Jan;125(1):437-47
pubmed: 25500884
J Virol. 2012 May;86(10):5915-21
pubmed: 22438535
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E6946-E6954
pubmed: 27791171
J Gen Virol. 2016 Nov;97(11):2883-2893
pubmed: 27667373
Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10149-54
pubmed: 15220475
Hepatology. 2014 Jun;59(6):2140-51
pubmed: 24425349
Hepatology. 2015 Dec;62(6):1670-82
pubmed: 26251214
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7418-22
pubmed: 23589879
Science. 2013 May 10;340(6133):751-6
pubmed: 23661761
J Hepatol. 2016 May;64(5):1020-1026
pubmed: 26780289
Methods Mol Biol. 2019;1911:441-450
pubmed: 30593644
Vaccine. 2010 Aug 31;28(38):6367-73
pubmed: 20619382
J Virol. 2000 Nov;74(22):10407-16
pubmed: 11044085
J Virol. 2016 Jan 06;90(6):3112-22
pubmed: 26739044
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7537-41
pubmed: 19380744
J Gen Virol. 2008 Mar;89(Pt 3):653-9
pubmed: 18272755